Baupost Group
13F Holdings and Portfolio Analysis
Seth Klarman 2016 Q4 13F holdings, quarterly changes, portfolio value trend and position weight distribution.
Baupost Group Overview
Baupost Group held 44 stocks in 2016 Q4, with total market value around $7.67B.
Baupost Group's top five holdings in 2016 Q4: CHENIERE ENERGY INC 11.74%, VIASAT INC(VSAT) 11.36%, Synchrony Financial(SYF) 9.77%, ALLERGAN PFD CONV SER A 9.40%, TWENTY FIRST CENTY FOX INC CL A(FOXA) 7.00%.
- Portfolio Value
- $7.67B
- Current Holdings
- 44 stocks
- New / Increased
- 13 / 9
- Reduced / Exited
- 3 / 13
Current Holdings
| 1 | CHENIERE ENERGY INCCUSIP 16411R208 | 0.90 | 11.74% | 21.73 -21.97% | $41.43 | - | $42.98 | -6.12 | 3.00 | -$0.03B-3.60% | Reduced |
| 2 | VIASAT INCVSAT | 0.87 | 11.36% | 13.16 +14.09% | $66.22 | - | $70.54 | +1.63 | 3.75 | -$0.06B-6.12% | Increased |
| 3 | Synchrony FinancialSYF | 0.75 | 9.77% | 20.66 +17.65% | $36.27 | $72.84 +100.83% | $29.24 | +3.10 | 0.50 | +$0.90B+149.11% | Increased |
| 4 | ALLERGAN PFD CONV SER ACUSIP G0177J108 | 0.72 | 9.40% | 3.43 +71.46% | $210.01 | - | $240.83 | +1.43 | 1.00 | -$0.11B-12.80% | Increased |
| 5 | TWENTY FIRST CENTY FOX INC CL AFOXA | 0.54 | 7.00% | 19.14 +50.14% | $28.04 | - | $26.77 | +6.39 | 1.50 | +$0.02B+4.72% | Increased |
| 6 | PBF ENERGY INCCUSIP 69318G106 | 0.44 | 5.72% | 15.72 - | $27.88 | - | $25.23 | 0.00 | 3.50 | +$0.04B+10.49% | Held |
| 7 | DELL TECHNOLOGIES INCCUSIP 24703L103 | 0.37 | 4.77% | 6.65 - | $54.97 | - | $47.80 | 0.00 | 0.50 | +$0.05B+15.00% | Held |
| 8 | ANTERO RES CORPCUSIP 03674X106 | 0.34 | 4.47% | 14.51 - | $23.65 | - | $13.71 | 0.00 | 2.50 | +$0.14B+72.48% | Held |
| 9 | THERAVANCE BIOPHARMA INCCUSIP G8807B106 | 0.30 | 3.85% | 9.27 +26.16% | $31.88 | - | $30.34 | +1.92 | 2.75 | +$0.01B+5.09% | Increased |
| 10 | NORTHSTAR ASSET MGMT GROUP ICUSIP 66705Y104 | 0.28 | 3.64% | 18.70 +88.68% | $14.92 | - | $13.87 | +8.79 | 0.50 | +$0.02B+7.61% | Increased |
| 11 | NORTHSTAR RLTY FIN CORPCUSIP 66704R803 | 0.22 | 2.88% | 14.58 +165.12% | $15.15 | - | $14.40 | +9.08 | 0.50 | +$0.01B+5.18% | Increased |
| 12 | TWENTY FIRST CENTY FOX INC CL BCUSIP 90130A200 | 0.20 | 2.59% | 7.28 - | $27.25 | - | $27.19 | 0.00 | 1.50 | +$0.00B+0.23% | Held |
| 13 | VERITIV CORPCUSIP 923454102 | 0.16 | 2.13% | 3.04 - | $53.75 | - | $46.74 | 0.00 | 2.50 | +$0.02B+15.01% | Held |
| 14 | INNOVIVA INCCUSIP 45781M101 | 0.16 | 2.08% | 14.93 - | $10.70 | - | $12.59 | 0.00 | 1.00 | -$0.03B-15.01% | Held |
| 15 | KERYX BIOPHARMACEUTICALS INCCUSIP 492515101 | 0.15 | 1.97% | 25.79 - | $5.86 | - | $14.16 | 0.00 | 3.00 | -$0.21B-58.62% | Held |
| 16 | COLONY CAP INCCUSIP 19624R106 | 0.14 | 1.84% | 6.96 +56.53% | $20.25 | - | $18.96 | +2.51 | 0.50 | +$0.01B+6.81% | Increased |
| 17 | MCKESSON CORP COMMCK | 0.14 | 1.83% | 1.00 | $140.45 | $742.44 +428.62% | $140.45 | +1.00 | 0.25 | +$0.60B+428.62% | New |
| 18 | FORWARD PHARMA A/SCUSIP 34986J105 | 0.08 | 1.05% | 5.37 - | $15.00 | - | $20.83 | 0.00 | 2.25 | -$0.03B-27.99% | Held |
| 19 | ATARA BIOTHERAPEUTICS INCCUSIP 046513107 | 0.08 | 0.99% | 5.36 - | $14.20 | - | $31.84 | 0.00 | 2.25 | -$0.09B-55.40% | Held |
| 20 | CARDINAL HEALTH INCCAH | 0.07 | 0.97% | 1.03 | $71.97 | - | $71.97 | +1.03 | 0.25 | $0.00B0.00% | New |
| 21 | LIBERTY BRAVES GROUP COMMON STOCKCUSIP 531229888 | 0.06 | 0.80% | 2.99 - | $20.59 | - | $14.66 | 0.00 | 0.75 | +$0.02B+40.45% | Held |
| 22 | AMERICAN INTL GROUP INCCUSIP 026874156 | 0.06 | 0.79% | 2.59 - | $23.46 | - | $16.22 | 0.00 | 3.75 | +$0.02B+44.60% | Held |
| 23 | SYNGENTA AGCUSIP 87160A100 | 0.06 | 0.77% | 0.75 | $79.05 | - | $79.05 | +0.75 | 0.25 | $0.00B0.00% | New |
| 24 | LIBERTY VENTURES COMMON STOCKCUSIP 53071M856 | 0.05 | 0.71% | 1.48 | $36.87 | - | $36.87 | +1.48 | 0.25 | $0.00B0.00% | New |
| 25 | CREDIT ACCEP CORP MICH COMCACC | 0.05 | 0.69% | 0.24 +144.40% | $217.51 | - | $204.24 | +0.14 | 0.75 | +$0.00B+6.50% | Increased |
Showing 1-25 of 44
"Holding Period (yrs)" is the latest uninterrupted holding duration, calculated by dividing continuous reported quarters by 4.
Cost basis is an estimate and can differ materially from the actual cost, especially in edge cases.
Cost basis estimate: from the latest uninterrupted holding period, new or increased shares are added to the cost pool at the report price; reductions remove shares at the then-average cost. Example: buy 100 shares at $10 in Q1 and add 50 shares at $16 in Q2, estimated cost basis is (100 x 10 + 50 x 16) / 150 = $12 per share.
Return shows estimated dollar return on top and percentage return below. It uses current price when available, otherwise report price.
Exited Holdings
Stocks no longer disclosed in the current 13F portfolio for 2016 Q4.
| 1 | PayPal Holdings, Inc.PYPL | 5.00 | 1.25 | $31.14 | $39.66 | +$0.04B+27.40% |
| 2 | OLIN CORPCUSIP 680665205 | 6.18 | 1.25 | $17.00 | $20.52 | +$0.02B+20.67% |
| 3 | VMWARE INCCUSIP 928563402 | 1.60 | 0.75 | $78.14 | $73.35 | -$0.01B-6.13% |
| 4 | LIBERTY VENTURES - SER A COMMON STOCK CL ACUSIP 53071M880 | 2.47 | 0.50 | $37.07 | $39.87 | +$0.01B+7.55% |
| 5 | CHIPMOS TECH BERMUDA LTDCUSIP G2110R114 | 3.75 | 3.50 | $18.79 | $19.80 | +$0.00B+5.35% |
| 6 | KLX INCCUSIP 482539103 | 2.00 | 1.75 | $36.60 | $35.20 | -$0.00B-3.83% |
| 7 | SILVER RUN ACQUISITION CORPCUSIP 82811P101 | 3.75 | 0.50 | $9.80 | $15.75 | +$0.02B+60.72% |
| 8 | Office Depot Inc. ComCUSIP 676220106 | 13.00 | 0.25 | $3.57 | $4.52 | +$0.01B+26.61% |
| 9 | CASCADIAN THERAPEUTICS INCCUSIP 14740B101 | 25.00 | 0.50 | $0.94 | $1.64 | +$0.02B+73.89% |
| 10 | SABAN CAP ACQUISITION CORPCUSIP 78516C205 | 2.33 | 0.25 | $10.08 | $10.08 | $0.00B0.00% |
| 11 | KINDRED BIOSCIENCES INCCUSIP 494577109 | 3.01 | 3.00 | $11.01 | $4.99 | -$0.02B-54.68% |
| 12 | TOBIRA THERAPEUTICS INCCUSIP 88883P101 | 0.16 | 0.25 | $39.74 | $39.74 | $0.00B0.00% |
| 13 | SILVER RUN ACQUISITION CORPCUSIP 82811P119 | 0.95 | 0.50 | $1.14 | $5.55 | +$0.00B+386.89% |
Showing 1-13 of 13
Exited holdings are stocks disclosed in the previous report period but no longer disclosed in the current 13F portfolio.
"Holding Period (yrs)" is the latest uninterrupted holding duration, calculated by dividing continuous reported quarters by 4.
Cost basis uses the same weighted cost-pool method as current holdings. Estimated exit price uses the current report period weighted report price when available, otherwise the previous report price; it does not represent the actual sale price.
Exit return shows estimated dollar return on top and percentage return below.
Portfolio Visuals
Track portfolio value, position weights and Top 10 history.